Published in BMJ on April 24, 2015
Safety of new oral anticoagulants. BMJ (2015) 1.40
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc (2016) 0.93
The evolution of anticoagulant therapy. Blood Transfus (2015) 0.86
The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. Br J Clin Pharmacol (2016) 0.77
Validity of peptic ulcer disease and upper gastrointestinal bleeding diagnoses in administrative databases: a systematic review protocol. BMJ Open (2016) 0.77
Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Saf (2016) 0.75
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data. Drug Saf (2015) 0.75
Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. Int J Cardiol (2016) 0.75
The Effect of Anesthetic Type on Outcomes of Hip Fracture Surgery: A Nationwide Population-Based Study. Medicine (Baltimore) (2016) 0.75
How we treat bleeding associated with direct oral anticoagulants. Blood Transfus (2016) 0.75
Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis. Sci Rep (2017) 0.75
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. Int J Clin Pract (2016) 0.75
Relationship between Early Physician Follow-Up and 30-Day Readmission after Acute Myocardial Infarction and Heart Failure. PLoS One (2017) 0.75
Anticoagulation therapy: Bleeding no worse with novel agents. Nat Rev Cardiol (2015) 0.75
Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol (2017) 0.75
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterol Res Pract (2016) 0.75
Meta-analysis should not be subject to selectivity and imbalance. BMJ (2015) 0.75
Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. Int J Gen Med (2016) 0.75
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res (2011) 13.63
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 7.15
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut (2011) 4.79
New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology (2013) 4.58
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation (2014) 3.53
Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods (2010) 2.99
National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes (2012) 2.27
Bleeding risk with dabigatran in the frail elderly. N Engl J Med (2012) 1.99
Casemix adjustment of managed care claims data using the clinical classification for health policy research method. Med Care (1998) 1.83
When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf (2012) 1.45
Dabigatran: how the drug company withheld important analyses. BMJ (2014) 1.42
Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open (2013) 1.40
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin (2014) 1.36
Dabigatran, bleeding, and the regulators. BMJ (2014) 1.29
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol (2012) 1.24
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost (2013) 1.15
Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. Circulation (2013) 1.15
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med (2014) 1.08
Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open (2014) 1.04
Upper GI bleeding requires prompt investigation. Practitioner (2011) 0.96
Continuation of dabigatran therapy in "real-world" practice in Hong Kong. PLoS One (2014) 0.88
Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban. Digestion (2014) 0.87
Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther (2013) 0.85